Drug Development Pipeline
Our lead program targets diabetic foot ulcers, a condition affecting millions of people and driving billions in healthcare costs each year.
Beyond DFUs, we are exploring plasminogen’s potential in other areas where healing fails or infection persists.
- Infections, including antibiotic-resistant bacteria
- Scarring and soft tissue regeneration
- Periodontitis
- Tympanic membrane perforations
- Idiopathic pulmonary fibrosis
Each represents a high-need area where plasminogen offers both biological rationale and early preclinical promise.
